Cargando…

Successful treatment of secondary poor graft function post allogeneic hematopoietic stem cell transplantation with eltrombopag

Poor graft function (PGF) is a life-threatening complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Current treatment strategies include the use of growth factors, CD34(+)-selected stem cell boost, mesenchymal stem cell transfusion, and second allo-HSCT, but these trea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tang, Cen, Chen, Feng, Kong, Danqing, Ma, Qinfen, Dai, Haiping, Yin, Jia, Li, Zheng, Chen, Jia, Zhu, Xiaming, Mao, Xinliang, Wu, Depei, Tang, Xiaowen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097332/ https://www.ncbi.nlm.nih.gov/pubmed/30115080 http://dx.doi.org/10.1186/s13045-018-0649-6

Ejemplares similares

Eltrombopag for the Treatment of Allogeneic Hematopoietic Stem Cell Transplantation-Related Poor Graft Function
por: Arslan Davulcu, Eren, et al.
Publicado: (2023)

Use of Eltrombopag in Improving Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation
por: Master, Samip, et al.
Publicado: (2018)

CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
por: Cui, Qingya, et al.
Publicado: (2021)

Eltrombopag for Post-Transplant Poor Graft Function in East Asian Patients
por: Ahn, Hyun Jin, et al.
Publicado: (2022)

Advances in the understanding of poor graft function following allogeneic hematopoietic stem-cell transplantation
por: Chen, Juan, et al.
Publicado: (2020)

P837: ELTROMBOPAG (EPAG) INDUCES HEMATOLOGIC RESPONSES FOR PATIENTS WITH POST-ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANT POOR GRAFT FUNCTION (POST-ALLO HSCT PGF): RESULTS OF THE ELTION STUDY IN SPAIN
por: Vallejo, C., et al.
Publicado: (2022)

PB2468: A RETROSPECTIVE STUDY OF ELTROMBOPAG IN PATIENTS WITH THROMBOCYTOPENIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: MA, Liangming, et al.
Publicado: (2023)

The Clinical Value of Procalcitonin in the Neutropenic Period After Allogeneic Hematopoietic Stem Cell Transplantation
por: Shan, Meng, et al.
Publicado: (2022)

The safety and short‐term outcomes of allogeneic hematopoietic stem cell transplantation with donor vaccination for COVID‐19
por: Ding, Yihan, et al.
Publicado: (2022)

Eltrombopag for the Treatment of Poor Graft Function Following Haematopoietic Cell Transplantation: Real-Life Data
por: Kırcalı, Ekin, et al.
Publicado: (2023)

Allogeneic hematopoietic stem cell transplantation from non-sibling 10/10 HLA-matched related donors: a single-center experience
por: Shen, Yaoyao, et al.
Publicado: (2021)

Risk-Factor Analysis of Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation
por: Xiao, Yang, et al.
Publicado: (2014)

CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia
por: Cao, Xuanqi, et al.
Publicado: (2022)

Eltrombopag for Treatment of Thrombocytopenia Following Hematopoietic Stem Cell Transplantation
por: Güven, Zeynep Tuğba, et al.
Publicado: (2022)

Efficacy of eltrombopag in thrombocytopenia after hematopoietic stem cell transplantation
por: KARATAŞ, Ayşe, et al.
Publicado: (2022)

Aberrant T cell responses in the bone marrow microenvironment of patients with poor graft function after allogeneic hematopoietic stem cell transplantation
por: Kong, Yuan, et al.
Publicado: (2017)

Rescue treatment with eltrombopag in refractory cytopenias after allogeneic stem cell transplantation
por: Aydin, Semra, et al.
Publicado: (2020)

Optimizing allogeneic grafts in hematopoietic stem cell transplantation
por: Xu, Zheng‐Li, et al.
Publicado: (2021)

Eltrombopag increases the hematopoietic supporting ability of mesenchymal stem/stromal cells
por: Muntión, Sandra, et al.
Publicado: (2022)

Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution
por: Maurer, Katie, et al.
Publicado: (2021)

Allogeneic hematopoietic cell transplantation, the microbiome, and graft-versus-host disease
por: van Lier, Yannouck F., et al.
Publicado: (2023)

Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia
por: Guan, Yihong, et al.
Publicado: (2022)

Successful Use of Eltrombopag in a Young Child With Chronic Immune Thrombocytopenia
por: Gruhn, Bernd, et al.
Publicado: (2021)

Case report: CD38-directed CAR-T cell therapy: A novel immunotherapy targeting CD38- positive blasts overcomes TKI and chemotherapy resistance of myeloid chronic myeloid leukemia in blastic phase
por: Cui, Qingya, et al.
Publicado: (2022)

Eltrombopag in Good's Syndrome
por: Kristiansen, Håvard Anton, et al.
Publicado: (2014)

Microbiota Predict Infections and Acute Graft-Versus-Host Disease After Pediatric Allogeneic Hematopoietic Stem Cell Transplantation
por: Margolis, Elisa B, et al.
Publicado: (2023)

Multipotent mesenchymal stromal cells as treatment for poor graft function after allogeneic hematopoietic cell transplantation: A multicenter prospective analysis
por: Servais, Sophie, et al.
Publicado: (2023)

Predicting Successful Hematopoietic Stem Cell Collection in Healthy Allogeneic Donors
por: Kayser, Sabine, et al.
Publicado: (2023)

Acute liver failure associated with human adenovirus infection after allogeneic hematopoietic stem cell transplantation
por: Lin, Zhimin, et al.
Publicado: (2023)

Adoptive Immunotherapy Against Allogeneic Kidney Grafts in Dogs with Stable Hematopoietic Trichimerism
por: Graves, Scott S., et al.
Publicado: (2008)

Graft conditioning with fluticasone propionate reduces graft‐versus‐host disease upon allogeneic hematopoietic cell transplantation in mice
por: Varady, Erika S, et al.
Publicado: (2023)

A case of immune thrombocytopenia associated with invasive thymoma successfully treated with eltrombopag
por: Yoon, Jung-Ki, et al.
Publicado: (2019)

Successful Eltrombopag Therapy in a Child with MYH9-Related Inherited Thrombocytopenia
por: Lassandro, Giuseppe, et al.
Publicado: (2022)

Successful Management of Ibrutinib-Induced Thrombocytopenia with Eltrombopag in a Patient with Waldenström Macroglobulinemia
por: Erçalışkan, Abdülkadir, et al.
Publicado: (2022)

The predictive value of pulmonary function test before transplantation for chronic pulmonary graft-versus-host-disease after allogeneic hematopoietic stem cell transplantation
por: Yang, Lingyi, et al.
Publicado: (2022)

Adding cyclosporin A to eltrombopag for aplastic anemia secondary to chemotherapy for solid cancers
por: Wan, Ziqi, et al.
Publicado: (2023)

Specific factors influence the success of autologous and allogeneic hematopoietic stem cell transplantation
por: Gonçalves, Thissiane L, et al.
Publicado: (2009)

Donor γδT Cells Promote GVL Effect and Mitigate aGVHD in Allogeneic Hematopoietic Stem Cell Transplantation
por: Song, Yuan, et al.
Publicado: (2020)

Primary Graft Failure after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies
por: Olsson, Richard F., et al.
Publicado: (2015)

The Incidence, Outcomes, and Risk Factors of Secondary Poor Graft Function in Haploidentical Hematopoietic Stem Cell Transplantation for Acquired Aplastic Anemia
por: Lin, Fan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3hhhk7ee6q5k97f7od4rob74st